Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients
© Cutuli et al.; licensee BioMed Central Ltd. 2014
Published: 17 March 2014
Endotoxin plays a crucial role in the pathogenesis of severe sepsis and septic shock (SS&SSh) . The aim of this study is to analyze the impact of extracorporeal endotoxin removal with polymyxin B hemoperfusion (PMX-DHP) (Toraymyxin®).
All patients admitted to our ICU between 1 April 2011 and 30 June 2013 who developed SS&SSh and underwent endotoxin activity assay (EAA) measurement were retrospectively evaluated.
Multivariate analysis for ICU mortality risk factors
OR (95% CI)
SAPS II score
1.1 (1.01 to 1.1;
10.4 (1.5 to 71)
0.2 (0.1 to 0.9)
0.1 (0.03 to 0.5)
EAA is a rapid and reliable method to identify patients who may be treated with polymyxin B hemoperfusion. Source control and extracorporeal endotoxin removal have appeared as two effective interventions that should be implemented in the early management of patients with SS&SSh.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.